VERTEX PHARMACEUTICALS INC / MA Debt Securities, Available-for-sale, Unrealized Loss Position
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $4.80 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $4.80B.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $3.40B.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $631.90M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $463.10M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $4.80B 10-Q · filed 2026-08-04 |
| 2026-03-31 | $3.40B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $631.90M 10-K · filed 2026-02-13 |
| 2025-09-30 | $463.10M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $816.00M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.10B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.20B 10-K · filed 2025-02-13 |
| 2024-09-30 | $443.80M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $4.60B 10-Q · filed 2024-08-02 |
| 2024-03-31 | $4.00B 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.50B 10-K · filed 2024-02-15 |
| 2023-09-30 | $2.28B 10-Q · filed 2023-11-07 |
| 2023-06-30 | $2.13B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $702.70M 10-Q · filed 2023-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |